Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are types of slow-growing cancers that affect a type of white blood cell called a lymphocyte. Lymphocytes are cells that help ...

Conditional survival is the probability that a patient with a given disease will survive an additional number of years based on the fact that he or she has already survived a specific number of years.

Approval is based on results from the BRUIN CLL-321 trial, the only randomized Phase 3 study in CLL/SLL in which all patients were previously treated with a covalent BTK inhibitor This expanded ...

New treatment options are outperforming the “old-fashioned” chemotherapy regimens for patients with CLL and SLL, according to Dr. Locke J. Bryan. Treatments for chronic lymphocytic leukemia (CLL) and ...

The National Comprehensive Cancer Network (NCCN) recommended zanubrutinib, approved by the FDA for the treatment of adult patients with mantle cell lymphoma, as a first-line and second-line therapy ...

Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met the primary endpoint for non-inferiority in terms of overall response rate in the first head-to-head comparison with ibrutinib ...

BEIJING, April 25, 2025--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company, announced today that its BTK inhibitor orelabrutinib received approval from ...

The U.S. Food and Drug Administration (FDA) has approved Brukinsa (zanubrutinib) for the treatment of the blood and bone cancers known as chronic lymphocytic leukemia (CLL) and small lymphocytic ...

A panel of experts explore current treatment strategies in CLL and SLL management. This is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA; Tara Graff, DO, MS; ...

When Nathan was diagnosed with chronic lymphocytic leukemia (CLL) at just 45 years old, his world turned upside down overnight. As a military veteran and ER nurse, he was no stranger to facing ...